The Japan Times - Drew Weissman, Nobel-winning mRNA pioneer

EUR -
AED 4.245913
AFN 76.887634
ALL 93.218842
AMD 422.094755
AOA 1060.176801
ARS 1724.882567
AUD 1.638747
AWG 2.082489
AZN 1.97002
BAM 1.955776
BBD 2.321671
BDT 142.688227
BHD 0.434695
BIF 3451.157116
BMD 1.156136
BND 1.477082
BOB 13.69983
BRL 5.876989
BSD 1.152686
BTN 109.688637
BWP 15.558807
BYN 3.432357
BYR 22660.258427
BZD 2.318271
CAD 1.61333
CDF 2615.761404
CHF 0.93588
CLF 0.026829
CLP 1055.916879
CNY 7.801146
CNH 7.796152
COP 3633.55485
CRC 523.993489
CUC 1.156136
CUP 30.637594
CVE 110.26363
CZK 24.258158
DJF 205.267449
DKK 7.477932
DOP 67.289164
DZD 152.967099
EGP 57.380687
ERN 17.342035
ETB 186.049588
FJD 2.553384
FKP 0.8566
GBP 0.858527
GEL 3.017966
GGP 0.8566
GHS 13.526832
GIP 0.8566
GMD 84.980421
GNF 10123.874202
GTQ 8.794891
GYD 241.157003
HKD 9.066767
HNL 30.895616
HRK 7.536622
HTG 150.718127
HUF 363.096405
IDR 20580.370421
ILS 3.468234
IMP 0.8566
INR 110.076256
IQD 1509.981237
IRR 1590322.371805
ISK 142.598215
JEP 0.8566
JMD 183.057725
JOD 0.819746
JPY 182.445186
KES 149.158147
KGS 101.104505
KHR 4681.941823
KMF 492.514185
KRW 1627.677557
KWD 0.356853
KYD 0.960588
KZT 540.233287
LAK 26025.676609
LBP 103223.017367
LKR 386.635196
LRD 208.057415
LSL 18.726567
LTL 3.413768
LVL 0.699335
LYD 7.331909
MAD 10.743067
MDL 20.044751
MGA 4918.938878
MKD 61.524236
MMK 2427.596601
MNT 4159.0218
MOP 9.314584
MRU 46.338424
MUR 54.419742
MVR 17.862733
MWK 1998.775164
MXN 19.812061
MYR 4.728715
MZN 73.882892
NAD 18.726567
NGN 1577.963717
NIO 42.419473
NOK 10.99759
NPR 175.501819
NZD 1.966719
OMR 0.442445
PAB 1.152686
PEN 3.903651
PGK 5.093937
PHP 70.183258
PKR 320.014324
PLN 4.299905
PYG 6853.914834
QAR 4.213648
RON 5.244583
RSD 117.338542
RUB 94.338828
RWF 1694.978938
SAR 4.329446
SBD 9.325039
SCR 16.705092
SDG 694.263698
SEK 10.961095
SGD 1.477585
SLE 28.445176
SOS 658.791814
SRD 43.778814
STD 23929.673396
STN 24.499696
SVC 10.085875
SZL 18.722767
THB 38.210709
TJS 10.633568
TMT 4.058036
TND 3.386358
TRY 55.144784
TTD 7.812903
TWD 37.286072
TZS 3051.762079
UAH 51.625959
UGX 4293.946644
USD 1.156136
UYU 46.399423
UZS 13785.828699
VES 873.763846
VND 30295.956222
VUV 138.059733
WST 3.160483
XAF 655.948849
XAG 0.018188
XAU 0.000266
XCD 3.124515
XCG 2.077474
XDR 0.81579
XOF 655.948849
XPF 119.331742
YER 275.626884
ZAR 18.667336
ZMK 10406.612213
ZMW 21.75673
ZWL 372.275202
  • CMSC

    0.0240

    21.744

    +0.11%

  • GSK

    0.7900

    52.96

    +1.49%

  • CMSD

    -0.1600

    21.82

    -0.73%

  • BTI

    0.6000

    59.33

    +1.01%

  • BCE

    -0.0200

    22.75

    -0.09%

  • RIO

    1.4500

    101.1

    +1.43%

  • RELX

    0.0485

    35.52

    +0.14%

  • RBGPF

    0.7600

    70.5

    +1.08%

  • NGG

    0.4700

    80.88

    +0.58%

  • BP

    -0.6000

    41.63

    -1.44%

  • RYCEF

    0.2300

    20.85

    +1.1%

  • JRI

    0.1500

    12.81

    +1.17%

  • BCC

    2.3400

    86.6

    +2.7%

  • VOD

    0.1900

    16.19

    +1.17%

  • AZN

    1.4100

    161.42

    +0.87%

Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman, Nobel-winning mRNA pioneer / Photo: Jonathan NACKSTRAND - AFP

Drew Weissman, Nobel-winning mRNA pioneer

Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.

Text size:

The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.

His next quests include, among others, developing a vaccine against all future coronaviruses.

"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.

"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."

- Twin breakthroughs-

The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.

But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.

"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.

In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.

"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.

"We sat there staring at our phones for five years, and they never rang!"

With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."

Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.

- Helping people -

Weissman grew up in Lexington, Massachusetts.

His father and mother, both since retired, were an engineer and dental hygienist, respectively.

"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.

He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.

As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.

Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.

"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.

Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.

Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.

Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.

Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.

M.Saito--JT